Preview Mode Links will not work in preview mode

Jan 4, 2024

Featuring perspectives from Dr Aditya Bardia, Dr Lisa A Carey, Dr Shanu Modi and Prof Peter Schmid, including the following topics: 
 
• Introduction (0:00)
• Optimal Approaches to HER2 Testing for the Identification of HER2-Low Breast Cancer — Dr Carey (3:27)
• Available Data with and Current Role of HER2-Targeted Therapy for HER2-Low Disease — Dr Modi (22:41)
• Identification and Management of Toxicities with Trastuzumab Deruxtecan — Prof Schmid (48:20)
• Future Directions in the Management of HER2-Low Breast Cancer — Dr Bardia (1:10:18)

CME information and select publications